Pharmos' Dexanabinol: latest
- Pharmos has reported that its neuroprotective drug Dexanabinol (HU-211) has shown promising results in animal models of stroke. The data were presented at the 3rd International Conference on Stroke in Prague, the Czech Republic, on October 25. In the study, rats which were subjected to temporary focal forebrain ischemia were injected intravenously with HU-211 after the ischemic insult. HU-211 significantly improved the neurological outcome of the ischemia three days after the insult, compared to vehicle, as measured by infarct size and brain swelling. A Phase I trial has been completed, and Phase II trials are planned for the beginning of 1996.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze